Member Articles
Battling COVID-19: Mechanisms for Access to Antiviral Products and Diagnostics
Related Articles inHealthcare & Pharmaceuticals | Life Sciences
More Healthcare & Pharmaceuticals | Life Sciences Aricles → Latest Firm's PressENSafrica IP landscape While the world is in the grip of the deadly COVID-19 pandemic, the patenting of pharmaceutical and biological compositions and the launch of generic products is even more hotly debated than before, particularly in the world's developing and least-developed countries. For many years, in the context of the devastating local HIV epidemic, organisations such as the Treatment Action Campaign and Medicines Sans Frontiers have challenged the government on the inadequacy of local IP laws to provide access to medicines. In particular, these organisations called on the government to amend the Patents Act to raise the bar in terms of which pharmaceutical companies would be able to register patents for drugs in South Africa. Partially in response to these calls, in 2018 the government published the Intellectual Property Policy of The Republic of South Africa Phase I (the IP Policy), which, among other things, proposes:
Further, the IP Policy addresses the government's use of the Doha Declaration provisions in terms of the Agreement on Trade-Related Aspects of Intellectual Property Rights to promote access to medicines for all through the use of government 'walk-in' rights in a national emergency, which would include a pandemic such as COVID-19. In addition, the IP Policy considers the use of parallel import measures provided for by the Medicines and Related Substances Act (the Medicines Act). Unfortunately, the legislative wheels turn slowly, so South Africa is left with the currently available options for access to diagnostic kits and reagents, drugs and biologics for the diagnosis and treatment or prevention of local COVID-19 infections. Therefore, what mechanisms are available at present to provide for access to medicines and diagnostics? Existing access to medicines provisions As mentioned, South Africa is a signatory to the Doha Declaration, which allows for measures to be taken to protect public health and promote access to medicines for all, including the use of compulsory licences, the terms on which these licences are granted and the right to determine which situations qualify to circumvent patent monopoly rights. At present, the Patents Act includes the following various provisions which give effect to the measures set out by the Doha Declaration:
Outside of the Patents Act, the Medicines Act includes measures supporting the supply of affordable medicines. Section 15C of the Medicines Act provides that the minister of health can, despite the Patents Act, limit certain rights of owners of medicines and, therefore, the infringing acts of third parties can be allowed in certain circumstances. In a more limited provision, the Medicines Act also sets out that the minister can prescribe conditions on which a generic medicine can be imported by a person that is not the holder of the registration certificate for a registered medicine. However, the medicine must have originated from the original manufacturer's site of manufacture. Patent revocation and infringement proceedings Another option, albeit a costly one, for generics manufacturers is to apply for revocation of a granted patent that is invalid. Any person may apply to the court to have a patent with invalid claims revoked. The court will make the decision as to whether to uphold or revoke the patent. In the event that the court decides that the patent should be upheld, it may do so with the condition that certain amendments are made. Where the court decides that amendments are necessary or where the patentee applies for amendments to be made during the revocation proceedings:
In infringement proceedings in respect of a patent which has been amended, the court may refuse to award damages in respect of any acts of infringement committed before the amendment. Further, the court may take into consideration the patentee's conduct in knowingly allowing the specification and claims to be maintained in an invalid form. The court may also consider the conduct of the patentee that has allowed the specification and claims to remain invalid when deciding the date from which damages are to be calculated. Patent infringement and Bolar provisions Before generics can be launched on the market, manufacturers must obtain registration from the South African Pharmaceuticals Regulatory Authority (SAHPRA). The requirements for registration of a generic drug before use or sale in South Africa include:
Importantly, South Africa has no research or scientific use exclusion in its Patents Act. Accordingly, scientific research on a patented invention may amount to an act of infringement. However, Section 69(A) of the Patents Act provides that it is not an act of infringement of a patent to make, use, exercise, offer to dispose of, dispose of or import the patented invention on a non-commercial scale solely for purposes reasonably relating to obtaining, developing and submitting information required under any law regulating the manufacture, production, distribution, use or sale of any product. Therefore, obtaining registration for a generic product before the expiry of the patented drug is not an infringing act under the Patents Act. This registration process for a generic drug is usually started by the generic manufacturer approximately five years before the expiry of a patent. However, stockpiling of a patented product is not allowed in terms of this section and will amount to infringement. Comment The reality is that the amendment of legislation is a lengthy process and, given the severity of the global COVID-19 pandemic, it is essential that the existing mechanisms for access to medicine are explored more vigorously and that the government is lobbied to be more proactive in putting these mechanisms to use, which would in turn be in keeping with South Africa's undertaking as a signatory to the Doha Declaration. For further information on this topic please contact Joanne van Harmelen at ENSafrica by telephone (+27 21 410 2500) or email ([email protected]). The ENSafrica website can be accessed at www.ensafrica.com.
|
Related Articles in
Healthcare & Pharmaceuticals | Life Sciences
- Life Sciences & Healthcare January/2021
March, 2021 - Bulletin Real Time: Latest News
March, 2021 - COVID-19 Products: Health Canada and Competition Bureau Watch Out for Misleading Claims
February, 2021 - Buchalter COVID-19 Client Alert: Cal-OSHA Wins First Round in Major Court Challenge to its COVID-19 Emergency Regulation
February, 2021
More Healthcare & Pharmaceuticals | Life Sciences Aricles →
Latest Firm's Press
ENSafrica